PRESS-RELEASE filed May 18, 2026 at 07:00 ET
NRx Pharmaceuticals reported Q1 2026 EPS of -$0.04, beating consensus of -$0.13 by 69.2%, with net loss narrowing to $1.4M from $5.5M a year ago. The company advanced multiple regulatory milestones including an anticipated FDA ANDA decision on preservative-free ketamine in Q3 2026, initiated commercial manufacturing, and generated first revenue from its HOPE Therapeutics clinic network. The beat is notable for a clinical-stage biotech but driven by non-recurring fair value accounting changes rather than operational improvement.